JP2020121990A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020121990A5 JP2020121990A5 JP2020068670A JP2020068670A JP2020121990A5 JP 2020121990 A5 JP2020121990 A5 JP 2020121990A5 JP 2020068670 A JP2020068670 A JP 2020068670A JP 2020068670 A JP2020068670 A JP 2020068670A JP 2020121990 A5 JP2020121990 A5 JP 2020121990A5
- Authority
- JP
- Japan
- Prior art keywords
- weight
- catechin
- flavanone
- group
- gallate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229930182470 glycoside Natural products 0.000 claims 11
- 150000002338 glycosides Chemical class 0.000 claims 11
- ZONYXWQDUYMKFB-UHFFFAOYSA-N SJ000286395 Natural products O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 claims 9
- 229930003949 flavanone Natural products 0.000 claims 9
- 235000011981 flavanones Nutrition 0.000 claims 9
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims 8
- 241000207199 Citrus Species 0.000 claims 8
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims 8
- 235000005487 catechin Nutrition 0.000 claims 8
- 229950001002 cianidanol Drugs 0.000 claims 8
- 235000020971 citrus fruits Nutrition 0.000 claims 8
- 150000002208 flavanones Chemical class 0.000 claims 8
- 235000020688 green tea extract Nutrition 0.000 claims 8
- 229940094952 green tea extract Drugs 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 claims 3
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims 3
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 claims 3
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 claims 3
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims 3
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 claims 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims 3
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 claims 3
- MZSGWZGPESCJAN-MOBFUUNNSA-N Melitric acid A Natural products O([C@@H](C(=O)O)Cc1cc(O)c(O)cc1)C(=O)/C=C/c1cc(O)c(O/C(/C(=O)O)=C/c2cc(O)c(O)cc2)cc1 MZSGWZGPESCJAN-MOBFUUNNSA-N 0.000 claims 3
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 3
- 150000001765 catechin Chemical class 0.000 claims 3
- 206010008118 cerebral infarction Diseases 0.000 claims 3
- 208000026106 cerebrovascular disease Diseases 0.000 claims 3
- 230000001419 dependent effect Effects 0.000 claims 3
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 claims 3
- 235000012734 epicatechin Nutrition 0.000 claims 3
- -1 epigalocatechin Chemical compound 0.000 claims 3
- SBHXYTNGIZCORC-ZDUSSCGKSA-N eriodictyol Chemical compound C1([C@@H]2CC(=O)C3=C(O)C=C(C=C3O2)O)=CC=C(O)C(O)=C1 SBHXYTNGIZCORC-ZDUSSCGKSA-N 0.000 claims 3
- TUJPOVKMHCLXEL-UHFFFAOYSA-N eriodictyol Natural products C1C(=O)C2=CC(O)=CC(O)=C2OC1C1=CC=C(O)C(O)=C1 TUJPOVKMHCLXEL-UHFFFAOYSA-N 0.000 claims 3
- 235000011797 eriodictyol Nutrition 0.000 claims 3
- SBHXYTNGIZCORC-UHFFFAOYSA-N eriodyctiol Natural products O1C2=CC(O)=CC(O)=C2C(=O)CC1C1=CC=C(O)C(O)=C1 SBHXYTNGIZCORC-UHFFFAOYSA-N 0.000 claims 3
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims 3
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 claims 3
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 claims 3
- 235000010209 hesperetin Nutrition 0.000 claims 3
- 229960001587 hesperetin Drugs 0.000 claims 3
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 claims 3
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 claims 3
- 235000007625 naringenin Nutrition 0.000 claims 3
- 229940117954 naringenin Drugs 0.000 claims 3
- 108050007366 40S ribosomal protein SA Proteins 0.000 claims 2
- 102100027271 40S ribosomal protein SA Human genes 0.000 claims 2
- 206010028289 Muscle atrophy Diseases 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 230000003266 anti-allergic effect Effects 0.000 claims 2
- 230000001093 anti-cancer Effects 0.000 claims 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims 2
- 230000003579 anti-obesity Effects 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 2
- 201000000585 muscular atrophy Diseases 0.000 claims 2
- 230000003449 preventive effect Effects 0.000 claims 2
- 206010003694 Atrophy Diseases 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000000883 anti-obesity agent Substances 0.000 claims 1
- 239000000043 antiallergic agent Substances 0.000 claims 1
- 239000003529 anticholesteremic agent Substances 0.000 claims 1
- 229940127226 anticholesterol agent Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940125710 antiobesity agent Drugs 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 235000013305 food Nutrition 0.000 claims 1
- 235000013376 functional food Nutrition 0.000 claims 1
- 230000002434 immunopotentiative effect Effects 0.000 claims 1
- 230000000091 immunopotentiator Effects 0.000 claims 1
- 239000000411 inducer Substances 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000001732 thrombotic effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014132891 | 2014-06-27 | ||
| JP2014132891 | 2014-06-27 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016529649A Division JP6912763B2 (ja) | 2014-06-27 | 2015-06-25 | カテキンの機能性増強法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020121990A JP2020121990A (ja) | 2020-08-13 |
| JP2020121990A5 true JP2020121990A5 (https=) | 2021-06-10 |
Family
ID=54938246
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016529649A Active JP6912763B2 (ja) | 2014-06-27 | 2015-06-25 | カテキンの機能性増強法 |
| JP2020068670A Pending JP2020121990A (ja) | 2014-06-27 | 2020-04-06 | カテキンの機能性増強法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016529649A Active JP6912763B2 (ja) | 2014-06-27 | 2015-06-25 | カテキンの機能性増強法 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US10251408B2 (https=) |
| JP (2) | JP6912763B2 (https=) |
| WO (1) | WO2015199169A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10251408B2 (en) * | 2014-06-27 | 2019-04-09 | Kyushu University, National University Corporation | Catechin function enhancement method |
| JP6881890B2 (ja) * | 2015-05-14 | 2021-06-02 | 花王株式会社 | カテキン類吸収促進剤 |
| US20190116835A1 (en) * | 2016-03-28 | 2019-04-25 | The Coca-Cola Company | Sweetness and Taste Improvement of Steviol Glycoside or Mogroside Sweeteners with Flavonids |
| JP7061303B2 (ja) | 2016-08-10 | 2022-04-28 | 国立大学法人九州大学 | ６７ｋＤａラミニンレセプター活性化剤及びその使用 |
| FR3061021B1 (fr) * | 2016-12-23 | 2020-04-03 | Etablissement Francais Du Sang | Antagoniste specifique de tlr4 dans le traitement du myelome multiple |
| KR102428987B1 (ko) * | 2017-05-16 | 2022-08-04 | (주)아모레퍼시픽 | 차나무의 추출물을 함유하는 조성물 |
| KR20190047873A (ko) | 2017-10-30 | 2019-05-09 | (주)아모레퍼시픽 | 특정 성분 함량이 증가된 차 추출물을 포함하는 지방대사 이상의 예방 및 개선용 조성물 |
| JP2019151568A (ja) * | 2018-03-01 | 2019-09-12 | アサヒ飲料株式会社 | 酸性スフィンゴミエリナーゼ活性向上剤、酸性スフィンゴミエリナーゼ活性向上用組成物、及び抗アレルギー用組成物 |
| WO2020096299A1 (ko) * | 2018-11-05 | 2020-05-14 | (주)아모레퍼시픽 | 성분 함량이 변화된 녹차 추출물, 및 이를 포함하는 조성물 |
| JP7364497B2 (ja) * | 2020-03-04 | 2023-10-18 | トヨタ自動車株式会社 | 緑茶抽出物含有組成物、機能性食品 |
| JP2022092966A (ja) * | 2020-12-11 | 2022-06-23 | トヨタ自動車株式会社 | ジペプチジルペプチダーゼｉｖ阻害剤、機能性表示食品 |
| WO2022164722A1 (en) * | 2021-01-28 | 2022-08-04 | Abbott Laboratories | Methods and nutritional compositions for improving muscle energy production and/or strength |
| JP2023008374A (ja) * | 2021-07-06 | 2023-01-19 | トヨタ自動車株式会社 | 抗肥満剤用組成物、機能性食品 |
| CN114990169B (zh) * | 2022-06-16 | 2023-07-28 | 中国农业科学院茶叶研究所 | 一种制备EGCG-3”-Me的方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08283154A (ja) * | 1995-04-12 | 1996-10-29 | Nippon Shinyaku Co Ltd | 脂質代謝改善剤 |
| US6379714B1 (en) | 1995-04-14 | 2002-04-30 | Pharmaprint, Inc. | Pharmaceutical grade botanical drugs |
| EP1063677B1 (en) | 1999-06-23 | 2005-03-16 | ICT Integrated Circuit Testing Gesellschaft für Halbleiterprüftechnik mbH | Charged particle beam device |
| EP1123304B1 (en) * | 1999-08-19 | 2003-10-08 | Korea Research Institute of Bioscience and Biotechnology | Flavonoids derived from citrus peels as collagen-induced platelet aggregation inhibitor |
| JP4246980B2 (ja) * | 2001-09-11 | 2009-04-02 | 花王株式会社 | 皮膚外用剤 |
| JP2004075619A (ja) * | 2002-08-20 | 2004-03-11 | Naris Cosmetics Co Ltd | タイプ２ヘルパーｔ細胞型サイトカイン抑制剤 |
| JP2005075805A (ja) * | 2003-09-03 | 2005-03-24 | Kyoto Univ | 酵素阻害剤 |
| US20110274680A1 (en) * | 2009-10-02 | 2011-11-10 | Mazed Mohammad A | Chemical composition and its delivery for lowering the risks of alzheimer's, cardiov ascular and type-2 diabetes diseases |
| JP5517421B2 (ja) * | 2007-08-03 | 2014-06-11 | 花王株式会社 | 容器詰飲料 |
| US10251408B2 (en) * | 2014-06-27 | 2019-04-09 | Kyushu University, National University Corporation | Catechin function enhancement method |
-
2015
- 2015-06-25 US US15/321,134 patent/US10251408B2/en active Active
- 2015-06-25 JP JP2016529649A patent/JP6912763B2/ja active Active
- 2015-06-25 WO PCT/JP2015/068302 patent/WO2015199169A1/ja not_active Ceased
-
2020
- 2020-04-06 JP JP2020068670A patent/JP2020121990A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020121990A5 (https=) | ||
| Wilcox et al. | Antiatherogenic properties of naringenin, a citrus flavonoid | |
| Puligundla et al. | Nanotechnological approaches to enhance the bioavailability and therapeutic efficacy of green tea polyphenols | |
| Pal et al. | Flavonoids: A powerful and abundant source of antioxidants | |
| Afshari et al. | Natural flavonoids for the prevention of colon cancer: A comprehensive review of preclinical and clinical studies | |
| Zanwar et al. | Antioxidant role of catechin in health and disease | |
| Coșarcă et al. | Therapeutic aspects of catechin and its derivatives–an update | |
| US10251408B2 (en) | Catechin function enhancement method | |
| Naderi et al. | Anti-oxidant effect of flavonoids on the susceptibility of LDL oxidation | |
| Narayana et al. | Bioflavonoids classification, pharmacological, biochemical effects and therapeutic potential | |
| Cherubini et al. | Black tea increases the resistance of human plasma to lipid peroxidation in vitro, but not ex vivo | |
| JP2003510240A (ja) | 癌治療として柑橘類リモノイド、フラボノイドおよびトコトリエノールの使用 | |
| Donovan et al. | Urinary excretion of catechin metabolites by human subjects after red wine consumption | |
| AU2007283267B2 (en) | Apples with high polyphenolic content | |
| US20020054924A1 (en) | Novel compositions derived from cranberry and grapefruit and therapeutic uses therefor | |
| TW200510542A (en) | Equol-producing lactic acid bacteria-containing composition | |
| EP1309333B1 (en) | Plant-derived and synthetic phenolic compounds and plant extracts, effective in the treatment and prevention of chlamydial infections | |
| AU2001282201A1 (en) | Plant-derived and synthetic phenolic compounds and plant extracts, effective in the treatment and prevention of chlamydial infections | |
| PL204232B1 (pl) | Zastosowanie związku fenolowego do wytwarzania leku przeznaczonego do leczenia i/ lub zapobiegania zakażeniom Chlamydiami | |
| Cao et al. | The genus Neolitsea of Lauraceae: a phytochemical and biological progress | |
| JP2005015469A (ja) | リモシトリンおよび５−デスメチルシネンセチンに関連する化合物を用いた腫瘍性疾患を抑制する組成物および方法 | |
| Hemshekhar et al. | Bone degeneration, inflammation and secondary complications of arthritis: potential targets and their natural inhibitors | |
| Deore et al. | Structure–activity relationship between flavonoids and chronic metabolic diseases | |
| Abtulov et al. | Flavonoids and the liver—a review | |
| Huseynova et al. | Flavonoids as chemosensitizers in leukemias |